Debiopharm and Takeda enters microbiome agreement to tackle GI disorders 17-Jun-2020 By Will Chu Debiopharm and Takeda are to embark on a license agreement and research collaboration that looks to develop novel microbiome therapeutics for the treatment of Gastro-Intestinal (GI) disorders.